Diverse role of survival motor neuron protein

RN Singh, MD Howell, EW Ottesen… - Biochimica et Biophysica …, 2017 - Elsevier
Abstract The multifunctional Survival Motor Neuron (SMN) protein is required for the survival
of all organisms of the animal kingdom. SMN impacts various aspects of RNA metabolism …

Emerging therapies and challenges in spinal muscular atrophy

MA Farrar, SB Park, S Vucic, KA Carey… - Annals of …, 2017 - Wiley Online Library
Spinal muscular atrophy (SMA) is a hereditary neurodegenerative disease with severity
ranging from progressive infantile paralysis and premature death (type I) to limited motor …

[HTML][HTML] Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy

D Chand, F Mohr, H McMillan, FF Tukov… - Journal of …, 2021 - Elsevier
Background & Aims Spinal muscular atrophy (SMA) is an autosomal recessive, childhood-
onset motor neuron disease. Onasemnogene abeparvovec (OA) is a gene therapy designed …

How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy

NN Singh, MD Howell, EJ Androphy, RN Singh - Gene therapy, 2017 - nature.com
Spinal muscular atrophy (SMA), a prominent genetic disease of infant mortality, is caused by
low levels of survival motor neuron (SMN) protein owing to deletions or mutations of the …

ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy

EW Ottesen - Translational neuroscience, 2017 - degruyter.com
Spinal muscular atrophy (SMA) is one of the leading genetic diseases of children and
infants. SMA is caused by deletions or mutations of Survival Motor Neuron 1 (SMN1) gene …

Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy

KK Long, KM O'Shea, RJ Khairallah… - Human Molecular …, 2019 - academic.oup.com
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by loss of α-motor
neurons, leading to profound skeletal muscle atrophy. Patients also suffer from decreased …

Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen

D Kariyawasam, A D'Silva, J Howells… - Journal of Neurology …, 2021 - jnnp.bmj.com
Objectives To elucidate the motor unit response to intrathecal nusinersen in children with
symptomatic spinal muscular atrophy (SMA) using a novel motor unit number estimation …

Therapeutic strategies for glucose transporter 1 deficiency syndrome

M Tang, SH Park, DC De Vivo… - Annals of clinical and …, 2019 - Wiley Online Library
Proper development and function of the mammalian brain is critically dependent on a steady
supply of its chief energy source, glucose. Such supply is mediated by the glucose …

[HTML][HTML] Challenges and future perspective of antisense therapy for spinal muscular atrophy: a review

Z Nakevska, T Yokota - European Journal of Cell Biology, 2023 - Elsevier
Spinal muscular atrophy (SMA), the most common genetic cause of infantile death, is
caused by a mutation in the survival of motor neuron 1 gene (SMN1), leading to the death of …

Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy

EW Ottesen, MD Howell, NN Singh, J Seo… - Scientific reports, 2016 - nature.com
Spinal muscular atrophy (SMA) is caused by low levels of survival motor neuron (SMN), a
multifunctional protein essential for higher eukaryotes. While SMN is one of the most …